Sold as H.P. Acthar Gel. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 1 application for Repository Corticotropin (sold as H.P. Acthar Gel), first approved Oct 15, 2010, with 0 new uses approved and 0 published complete response letters.
| Study | Phase | Status | Posted |
|---|---|---|---|
| Corticotropin for Behçet's Disease: A Multicenter Randomized Controlled TrialAcronym.Behçet's Syndrome, Behçet's Syndrome (BS) · Peking University People's Hospital | Phase 2 | Not yet recruiting | Sep 22, 2026 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Oct 15, 2010 | H.P. Acthar GelNDA 22432 · TYPE 6 | Questcor Pharma | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA